Thyroid cancer; diagnosis

Diagnostic agents

Absorptin median Tmax: 10 hrs
Elimination half life: 25 hrs

N/A

N/A

N/A

>10%: Gastrointestinal: Nausea (11%)
1% to 10%:
Central nervous system: Headache (6%), dizziness (2%), fatigue (2%)
Gastrointestinal: Vomiting (2%)
Neuromuscular & skeletal: Weakness (1%)
Frequency not defined: Endocrine & metabolic: Altered thyroid hormone levels (increased)
<1%, postmarketing, and/or case reports: Cerebrovascular accident (with and without physiologic symptoms like unilateral weakness), flu-like symptoms (transient; including arthralgia, chills, fever, malaise, myalgia, shivering), hypersensitivity reaction (including dyspnea, flushing, pruritus, skin rash, urticaria), injection site reaction (including bruising, erythema, pain, and pruritus)

0.9 mg IM every 24 hours for 2 doses; consider premedication with glucocorticoids if local tumor expansion may compromise vital anatomic structures.

N/A

There are no dosage adjustments provided in the manufacturer’s labeling; however, elimination is significantly slower in dialysis-dependent end-stage renal impairment and TSH level elevation may be prolonged.

N/A

Refrigerate vials between 2 and 8 oC and protect from light; diluted solution can be stored between 2 and 8 oC for 24 hrs if necessary